174 related articles for article (PubMed ID: 16530503)
1. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
Kamal SM; Fouly AE; Kamel RR; Hockenjos B; Al Tawil A; Khalifa KE; He Q; Koziel MJ; El Naggar KM; Rasenack J; Afdhal NH
Gastroenterology; 2006 Mar; 130(3):632-8. PubMed ID: 16530503
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
3. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
[TBL] [Abstract][Full Text] [Related]
4. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G;
Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Lindsay KL; Trepo C; Heintges T; Shiffman ML; Gordon SC; Hoefs JC; Schiff ER; Goodman ZD; Laughlin M; Yao R; Albrecht JK;
Hepatology; 2001 Aug; 34(2):395-403. PubMed ID: 11481625
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
Liu CH; Liang CC; Liu CJ; Lin JW; Chen SI; Hung PH; Tsai HB; Lai MY; Chen PJ; Chen DS; Kao JH
Clin Infect Dis; 2010 Sep; 51(5):541-9. PubMed ID: 20645865
[TBL] [Abstract][Full Text] [Related]
8. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
10. Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.
Neumann AU; Pianko S; Zeuzem S; Yoshida EM; Benhamou Y; Mishan M; McHutchison JG; Pulkstenis E; Mani Subramanian G
J Hepatol; 2009 Jul; 51(1):21-8. PubMed ID: 19447518
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
J Hepatol; 2006 Jan; 44(1):97-103. PubMed ID: 16290907
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Sánchez-Tapias JM; Diago M; Escartín P; Enríquez J; Romero-Gómez M; Bárcena R; Crespo J; Andrade R; Martínez-Bauer E; Pérez R; Testillano M; Planas R; Solá R; García-Bengoechea M; Garcia-Samaniego J; Muñoz-Sánchez M; Moreno-Otero R;
Gastroenterology; 2006 Aug; 131(2):451-60. PubMed ID: 16890599
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
Jacobson IM; Brown RS; Freilich B; Afdhal N; Kwo PY; Santoro J; Becker S; Wakil AE; Pound D; Godofsky E; Strauss R; Bernstein D; Flamm S; Pauly MP; Mukhopadhyay P; Griffel LH; Brass CA;
Hepatology; 2007 Oct; 46(4):971-81. PubMed ID: 17894303
[TBL] [Abstract][Full Text] [Related]
14. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
[TBL] [Abstract][Full Text] [Related]
16. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
Reddy KR; Shiffman ML; Morgan TR; Zeuzem S; Hadziyannis S; Hamzeh FM; Wright TL; Fried M
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):124-9. PubMed ID: 17196435
[TBL] [Abstract][Full Text] [Related]
17. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.
Mangia A; Minerva N; Bacca D; Cozzolongo R; Ricci GL; Carretta V; Vinelli F; Scotto G; Montalto G; Romano M; Cristofaro G; Mottola L; Spirito F; Andriulli A
Hepatology; 2008 Jan; 47(1):43-50. PubMed ID: 18069698
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.
Zeuzem S; Hultcrantz R; Bourliere M; Goeser T; Marcellin P; Sanchez-Tapias J; Sarrazin C; Harvey J; Brass C; Albrecht J
J Hepatol; 2004 Jun; 40(6):993-9. PubMed ID: 15158341
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa-2a in patients with chronic hepatitis C.
Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
